Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Investment will fund expansion to meet rising demand for CRDMO services
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client
The biosimilar Ustekinumab has been developed and manufactured by the company
ICMR will continue to track trends in HMPV circulation throughout the year
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Subscribe To Our Newsletter & Stay Updated
